Loopbaan van Christophe Quéva
Eerdere bekende functies van Christophe Quéva
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
ONCORUS, INC. | Chief Tech/Sci/R&D Officer | 01-10-2017 | 01-09-2022 |
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Chief Tech/Sci/R&D Officer | 01-08-2015 | 01-09-2017 |
GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01-01-2012 | 01-07-2015 |
AMGEN INC. | Corporate Officer/Principal | 01-01-2006 | 01-01-2011 |
Opleiding van Christophe Quéva
Université De Lille | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 4 |
België | 2 |
Frankrijk | 2 |
Operationeel
Chief Tech/Sci/R&D Officer | 2 |
Corporate Officer/Principal | 2 |
Doctorate Degree | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 3 |
---|---|
AMGEN INC. | Health Technology |
GILEAD SCIENCES, INC. | Health Technology |
ONCORUS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
iTeos Therapeutics SA
iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Health Technology |
- Beurs
- Insiders
- Christophe Quéva
- Ervaring